Finn Brooks: Juniper, hey — okay I have been stewing on this since Monday and I need to get into it.
Juniper Vale: I can tell. You texted me at like 6 a.m.
Finn Brooks: Because Vertex just dropped ten billion dollars — ten billion, eighty-five dollars a share — on Crinetics Pharmaceuticals, and half of that bet is sitting on a drug that has not cleared a single regulatory hurdle. Atumelnant is still investigational. Still Phase 3. And Reshma Kewalramani is out there calling the Phase 2 data 'flooring.'
Juniper Vale: Okay but the market already told us who won this deal.
Finn Brooks: Wait — you're going to defend this?
Juniper Vale: Crinetics shares went up roughly ninety-nine percent on announcement day. That's a near-doubling overnight. So I mean — someone walked away very happy.
Finn Brooks: Right — Crinetics won, I'm not arguing that! But Vertex shares dipped. Their own shareholders sold off. That's the split. And that's actually what we're trying to work out today — is this Vertex's boldest pivot ever, or did they just leverage themselves to the hilt on a hope? Because Vertex projects over five billion in combined peak annual revenue from PALSONIFY and atumelnant, and atumelnant isn't even approved yet.
Juniper Vale: And this is Vertex's largest-ever acquisition. That context matters.
Finn Brooks: And that context is actually what makes this so wild — like, think about the shape of what they bought. PALSONIFY is real. FDA approved September 2025, EMA approved, first-ever once-daily oral pill for acromegaly. That part is done. But atumelnant? That's carrying, what, the bulk of the five-billion-plus revenue projection? On Phase 2 data?
Juniper Vale: Think of it like buying a house where the seller shows you one finished bedroom — beautiful, move-in ready — and then hands you a blueprint for four more. The finished room is PALSONIFY. Patients with acromegaly, a rare disorder where your body overproduces growth hormone, finally get a pill instead of injections twice a week. That's real. The blueprint is atumelnant.
Finn Brooks: And the blueprint is where the money is.
Juniper Vale: The blueprint is where almost all the money is, yeah. Atumelnant — targeting congenital adrenal hyperplasia and Cushing syndrome — that's the engine of the projection. And it has not been approved. It's still investigational. Still Phase 3.
Finn Brooks: And Reshma Kewalramani said she was — her word — 'floored' by the Phase 2 data. Which, I mean, I get it, Phase 2 can look incredible. But Phase 2 excitement has preceded Phase 3 failures more times than anyone in this industry wants to say out loud.
Juniper Vale: No, that's my flag too — that's exactly where I'd plant it. Being floored by Phase 2 is not the same as Phase 3 clearance. Those are not the same thing.
Finn Brooks: Wait, so does Vertex — do they have a Plan B if atumelnant doesn't clear? Like, does PALSONIFY alone justify anywhere near ten billion dollars?
Juniper Vale: I mean — almost certainly not at that valuation. PALSONIFY is genuinely important for acromegaly patients, I don't want to undersell that. But rare disease, first pill, one indication? That's not a ten-billion-dollar asset on its own. The number only makes sense if atumelnant hits.
Finn Brooks: So the entire bet lives or dies in Phase 3. That's the actual story.
Juniper Vale: And it does — but that's actually where the identity question starts to bite, because Vertex isn't just betting on Phase 3. They're financing a ten-billion-dollar deal with cash on hand and debt. They are leveraged now. On a company in a therapeutic area they have never commercially operated in.
Finn Brooks: Wait — Evan Seigerman at BMO Capital Markets literally compared this move to what Gilead and Biogen did when they expanded. Like, those are the companies Vertex wants to become. And the irony is — Vertex got to the position where they could make this bet because they stayed obsessively focused on cystic fibrosis for two decades. That CF cash machine is the only reason this deal exists.
Juniper Vale: No, that's real. I'm not disputing that.
Finn Brooks: But then — okay wait, that's actually the contradiction — you succeed by being the world's best at one thing, and then you use that success to become something different? Rare endocrinology has totally different doctors, different — I mean, the commercial infrastructure, the key opinion leaders, the biology — it's a different world.
Juniper Vale: Okay, I'd actually push back on how different it really is. Vertex's whole competency is rare disease — small patient populations, high unmet need, regulatory complexity. Acromegaly, congenital adrenal hyperplasia — those are rare. That's still the same corridor. But the debt piece, yeah, that's the part I can't wave away. You're leveraged on a Phase 3 that hasn't read out.
Finn Brooks: And it's not just Vertex doing this right now — that's what's wild. Novartis, Ipsen, United Therapeutics, Vertex — all four announced acquisitions in the first six days of July. Six days. And before that, 45 biotech companies had already sealed M&A exits in the first half of 2026 alone.
Juniper Vale: Which — I mean, that changes what this is. If it's a pattern, then Vertex isn't being bold, they're being... reactive? Like, everyone bought at once, which makes me wonder if the desperation thesis has more teeth than the ambition thesis.
Finn Brooks: That's exactly the question — and Reshma Kewalramani framing this as an 'excellent strategic fit' targeting serious diseases with significant unmet need, that's the ambition language. But ambition and desperation can look identical from the outside.
Juniper Vale: And whether this consolidation wave actually ends up helping patients or just shuffling assets between balance sheets — that's the part I want to get into, and I'll be honest, where I'm not sure I land yet.
Finn Brooks: And that patient question is actually where I keep getting stuck — because if consolidation is the pattern, if four deals in six days is the new normal, then you end up with fewer Crinetics-type biotechs competing in rare endocrinology. Like, who's keeping prices honest if the independents keep getting absorbed?
Juniper Vale: Fewer competing drug developers, less competitive pressure on pricing. That's not a hypothetical — that's a structural consequence. And I'll be honest, that part I can't argue away.
Finn Brooks: Wait — so you're conceding the market signal too? Because Vertex shares dipped.
Juniper Vale: Yeah, I am. The net equity on Crinetics after cash acquired sits around $8.8 billion, and the implied multiple on an unapproved drug — atumelnant is still investigational — I mean, that is genuinely hard to defend on a spreadsheet. Crinetics investors won this trade, Vertex shareholders are right to be cautious. I'm not going to pretend the market got that wrong.
Finn Brooks: Ninety-nine percent surge versus a dip. That's not ambiguous.
Juniper Vale: No, it's not. But — and this is where I'm holding — the valuation risk and the patient-access question are two separate problems. The market being skeptical of Vertex's price doesn't tell us anything about what happens to rare disease competition when Novartis, Ipsen, United Therapeutics, and Vertex all vacuum up independents inside one week.
Finn Brooks: Okay I love that framing, BUT — doesn't the Phase 3 readout on atumelnant basically answer both questions at once? Like, if it clears, Vertex justified the multiple and a large well-resourced company is now driving CAH treatment forward. If it fails, the whole consolidation-as-progress story collapses anyway.
Juniper Vale: That's — actually, no, I don't think it does. Because even if atumelnant clears Phase 3, that's one drug, one company. The question is what the wave of consolidation means for the next Crinetics — the one that hasn't been bought yet. That company may not exist in five years. And that's the gap I'm not closing.
Finn Brooks: And that's — Q4 2027, Q1 2028, somewhere in that window. That's when atumelnant's Phase 3 data reads out. That's the verdict. And whatever Reshma Kewalramani said about Phase 2, whatever the strategic vision deck looked like — none of it matters until that number comes back.
Juniper Vale: And if it misses — I mean, the market won't reconstruct the thesis. They won't remember the rare endocrinology pivot or the unmet need argument. They'll remember that a company built its entire reputation by staying focused, by being the best in the world at cystic fibrosis, and then paid ten billion dollars to become Gilead. And didn't.
Finn Brooks: Back to that six a.m. text I sent you.
Juniper Vale: Which was, basically — is this bold or is this desperate? And I don't think we closed that. I'm okay with that.
